NCT02678351View on ClinicalTrials.gov

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 18, 2016

Primary Completion Date

December 13, 2020

Study Completion Date

December 31, 2021

Conditions

Stage II Prostate AdenocarcinomaStage III Prostate Adenocarcinoma

Interventions

DRUG

68Ga-PSMA-11

Undergo 68Ga-PSMA-11 PET/MRI

PROCEDURE

Magnetic resonance imaging (MRI)

Undergo 68Ga-PSMA-11 PET/MRI

PROCEDURE

Positron Emission Tomography (PET)

Undergo 68Ga-PSMA-11 PET/MRI

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Andrei Iagaru

OTHER

NCT02678351 - 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery | Biotech Hunter | Biotech Hunter